2019 Deals Review and Deals in China

Time:14:30~15:15 18 June (UTC+8)

With the decrease ROI in R & D spending, pharmaceutical companies are trying to grab the market share with Licensing or M&A as much as they can. On the one hand, they become cautious and discerning in transactions; on the other hand, they spend a lot of money on high-quality assets. The market has more uncertainty in 2020 due to the impact of coronavirus. Still, it does not seem to prevent the life science people from moving forward, either to begin clinical trial rapidly or to speed up a large number of mergers and acquisitions. Ms. Zhao Yuwei, from Clarivate, will review the major deals with you in the pharmaceutical field in the past year and will review and comment on the deals of the Chinese market. We believe the 2019 Deals Review and Deals in China will support your business decisions in the future.

Speaker

Tina Zhao

Life Sciences Solution Consultant, Clarivate

Tina has 13 years of experience in IP industry and life science industry. She joined Clarivate Analytics in 2015 as solution consultant for LS and IP products and services to support clients in the pharmaceutical industry for business development, market accessment, portfolio management, and IP risk management.  She graduated from National Taiwan University and has an M.S. degree in biochemistry and. She passed China Patent Attorney Bar Examination in 2014.